Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis

Hauser, S.; Bar-Or, A.; Comi, G.; Giovannoni, G.; Hartung, Hans-Peter; Hemmer, B.; Lublin, F.; Montalban, X.; Rammohan, K.; Selmaj, K.; Traboulsee, A.; Wolinsky, J.; Arnold, D.; Klingelschmitt, G.; Masterman, D.; Fontoura, P.; Belachew, S.; Chin, P.; Mairon, N.; Garren, Hideki; Kappos, L.

doi:10.1056/NEJMoa1601277

Public

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Shared by NobleBlocks on Dec 21, 2016 • 12:00 AM UTC

Authors:

Stephen L. Hauser

Amit Bar‐Or

Gıancarlo Comı

Abstract

BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous o...

Subject

Ocrelizumab

Medicine

Interferon beta-1a

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!